Clinical trials · Pennsylvania
Peritoneal Cancer clinical trials in Pennsylvania
We’re tracking 36 recruiting peritoneal cancer studies with a site in Pennsylvania — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Pennsylvania
- NCT06890338RecruitingPhase 2
Carboplatin and mirvetuximab for advanced ovarian cancer
This trial tests a combination of chemotherapy (carboplatin) and a targeted drug (mirvetuximab soravtansine) given through a vein. It is for people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific protein called folate receptor alpha (FRα) on at least 75% of tumor cells.
Bethlehem, PennsylvaniaAges 18 years+ - NCT04657068RecruitingPhase 1/Phase 2
Study of ART0380 for advanced solid tumors
This study tests a new drug called ART0380 for people with advanced solid tumors that have not responded to standard treatments. It may be especially helpful for those with certain DNA repair gene changes (like ATM or BRCA). The drug will be given alone or with chemotherapy (gemcitabine or irinotecan) depending on the part of the trial.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04606914RecruitingPhase 2
Carboplatin plus mirvetuximab for advanced ovarian cancer after chemo
This Phase 2 study tests adding mirvetuximab to carboplatin for people with advanced, high-grade serous ovarian cancer who will first receive “neoadjuvant” chemotherapy. It is designed for tumors that strongly show FRα, which mirvetuximab targets, to see if this improves outcomes.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT04575935RecruitingPhase 3
Minimally invasive surgery after chemotherapy for advanced ovarian cancer
This trial studies whether doing surgery using smaller incisions after chemotherapy works as well as a more traditional approach for certain people with stage IIIC–IV ovarian, fallopian tube, or primary peritoneal cancer. It may help reduce surgical trauma while aiming for effective tumor removal.
Bethlehem, PennsylvaniaAges 18 years+ - NCT05659381RecruitingPhase 3
Heated belly chemo plus niraparib after interval surgery for ovarian cancer
This Phase 3 study tests whether heated chemotherapy placed inside the belly, followed by interval surgery and the maintenance medicine niraparib, can improve outcomes for certain advanced ovarian, fallopian tube, or primary peritoneal cancers. It focuses on people whose tumors are HRD/LOH positive and who can have all visible disease removed.
Wexford, PennsylvaniaAges 18 years+ - NCT07001592RecruitingPhase 1
Injection of a modified virus for advanced GI and peritoneal cancers
This trial tests a modified virus injected directly into tumors to treat metastatic gastrointestinal and peritoneal cancers. It aims to see if this approach can shrink tumors or slow their growth.
Pittsburgh, PennsylvaniaAges 18–69 - NCT07282834RecruitingPhase 2
Comparing two types of heated chemo for abdominal cancer spread
This trial tests if giving heated chemotherapy as a mist (aerosol) is better than as a liquid for cancer that has spread to the lining of the abdomen. It is for people who have already had at least three months of standard chemo but still have disease and cannot have surgery right now.
Pittsburgh, PennsylvaniaAges 18–80 - NCT05071937RecruitingPhase 2
Talazoparib plus ZEN003694 for recurrent ovarian cancer
This Phase 2 trial tests whether combining ZEN003694 with talazoparib can slow or shrink recurrent ovarian, fallopian tube, or primary peritoneal cancer. It is designed for people who have already been treated with a PARP inhibitor before, and it may help if that cancer comes back.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05867251RecruitingPhase 1/Phase 2
AVZO-021 for advanced breast and ovarian cancers
This early-stage study tests AVZO-021, a new anti-cancer medicine, in people with advanced solid tumors like specific types of breast and ovarian (or related) cancers. It’s meant to find the safest dose and look for signs the medicine can shrink tumors, especially in cancers with certain gene changes.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04590326RecruitingPhase 1/Phase 2
Study of REGN5668 with or without immunotherapy in ovarian cancer
This Phase 1/2 study tests how safe REGN5668 is and how well it works in adult women with advanced gynecologic cancers. It compares REGN5668 given with cemiplimab alone, or cemiplimab plus fianlimab, and looks for responses in tumors that meet specific criteria.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06682988RecruitingPhase 2
New treatment for advanced ovarian cancer
This trial tests a drug called mirvetuximab soravtansine for people with platinum-resistant ovarian, peritoneal, or fallopian tube cancer that has high levels of a protein called folate receptor-alpha (FRα). It is given through a vein (IV) and aims to stop cancer from growing.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05281471RecruitingPhase 3
Tested drug for platinum-resistant ovarian cancer with bevacizumab
This Phase 3 trial tests a treatment made of an investigational gene-based drug plus standard “platinum” chemotherapy and bevacizumab, compared with standard chemotherapy and bevacizumab. It’s for ovarian/fallopian tube/primary peritoneal cancers that have not responded to platinum chemotherapy or came back quickly.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06617923RecruitingPhase 2
Senaparib and Temozolomide for ARID1A-Mutated Ovarian Cancer
This trial tests a combination of two drugs, senaparib and temozolomide, for women with a specific type of ovarian cancer that has come back or is resistant to platinum-based chemotherapy. It is for patients whose tumor has a change in the ARID1A gene.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06906341RecruitingPhase 2
Relacorilant combo for gynecologic cancers
This trial tests a drug called relacorilant combined with different treatments for ovarian, fallopian tube, primary peritoneal, or endometrial cancers. It may help patients whose cancer has stopped responding to standard therapies.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06787612RecruitingPhase 2
New combination for platinum-resistant ovarian cancer
This study tests a new combination treatment (ubamatamab plus another drug) for people with ovarian cancer that no longer responds to platinum chemotherapy. It could be an option if your cancer has kept growing despite prior treatment.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05887609RecruitingPhase 2
Maintenance treatment for FRalpha-positive ovarian or endometrial cancer
This Phase 2 trial tests a combination of two medicines (mirvetuximab soravtansine and olaparib) as ongoing “maintenance” treatment after your best response to prior platinum chemotherapy. It may help keep cancer from growing longer in certain women whose tumors strongly match a specific marker (FRalpha).
Philadelphia, PennsylvaniaAges 18–100 - NCT06690775RecruitingPhase 2
Study of a new drug for platinum-resistant ovarian cancer
This trial tests an investigational drug called TORL-1-23 for people with ovarian cancer that has stopped responding to platinum chemotherapy. It aims to see if the drug can help shrink or control the cancer.
Doylestown, PennsylvaniaAges 18 years+ - NCT06824467RecruitingPhase 3
Maintenance Therapy Study for Recurrent Ovarian Cancer
This study tests a new maintenance treatment (sacituzumab tirumotecan) versus standard care for people with ovarian cancer that has come back after responding to platinum-based chemotherapy. The goal is to see if it can keep the cancer from growing longer and improve quality of life.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05579366RecruitingPhase 1/Phase 2
Study drug for advanced ovarian and other solid cancers
This Phase 1/2 trial studies Rinatabart Sesutecan to treat advanced cancers, with special focus on certain ovarian cancer types. It’s meant for people whose cancer has come back or has not responded to prior treatments.
Doylestown, PennsylvaniaAges 18 years+ - NCT05128825RecruitingPhase 2
Test drug azenosertib for platinum-resistant ovarian cancer
This Phase 2 trial tests azenosertib to treat platinum-resistant high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. It looks for whether the drug can shrink tumors and improve outcomes in people whose cancer has returned after platinum chemotherapy.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06469281RecruitingPhase 1
A new immune cell therapy for recurring ovarian cancer
This early-phase trial tests a new immune cell therapy called 27T51, which targets a protein called MUC16 found on ovarian cancer cells. The study is for people with recurrent or treatment-resistant ovarian, primary peritoneal, or fallopian tube cancer to see if the therapy is safe and works when given alone or with other treatments.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT02637934RecruitingPhase 1
PET scan tracer study for ovarian or related cancers
This early study tests a radioactive tracer (given as an injection) and tracks how it moves through the body using PET/CT scans. It may help doctors better understand how this tracer behaves in cancers of the ovaries, fallopian tubes, or the lining of the abdomen.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05538091RecruitingPhase 2
Testing vismodegib plus atezolizumab for platinum-resistant ovarian cancer
This Phase 2 trial tests whether combining vismodegib with atezolizumab can slow or shrink platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. It targets cancers that grow again within 6 months after platinum chemotherapy.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07277413RecruitingPhase 1
Study of IDE892 for advanced solid tumors with MTAP deletion
This study tests a new drug called IDE892, alone or in combination, for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and whether it can shrink tumors.
Philadelphia, PennsylvaniaAges 18 years+
Peritoneal Cancer trials by city in Pennsylvania
Where these studies are running in Pennsylvania
Institutions with a site for the recruiting peritoneal cancer studies listed above.
- University of Pennsylvania · 6 studies
- West Penn Hospital · 5 studies
- Allegheny Health Network · 4 studies
- Thomas Jefferson University Hospital · 4 studies
- Alliance Cancer Specialists · 2 studies
- University of Pittsburgh Medical Center · 2 studies
- UPMC Hillman Cancer Center · 2 studies
- 127
What taking part in a peritoneal cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there peritoneal cancer clinical trials in Pennsylvania?
- Yes. We're currently tracking 36 recruiting peritoneal cancer studies with a site in Pennsylvania, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a peritoneal cancer study in Pennsylvania?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Pennsylvania to take part?
- Not necessarily. These studies have a site in Pennsylvania, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a peritoneal cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New peritoneal cancer studies open in Pennsylvania regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.